Meet the Translation team

Translation team


The Crick’s Translation team helps connect scientists with industry colleagues, clinicians, drug discovery experts, technology experts and investors, who can help turn discoveries in the lab into potential new treatments and technologies to benefit patients.

We work with individual research groups to guide projects through different phases of development, providing advice, funding and connections with external partners. We focus on long-term impact, rather than short-term revenue generation.

With strong track records in translation and research, we are fully integrated within the day-to-day scientific life of the Crick, and provide easy access to expertise to accelerate ideas towards patient benefit.

The team also supports the wider UK translational research environment, through participation on funding committees, university and company boards and seed investment funds.

Translation Advisory Group

Our Translation Advisory Group of industry and academic scientists, funders and entrepreneurs, offers expert insight and support translation at the Crick by:

  • advising on funding for translational projects proposed by researchers at the Crick
  • reviewing project plans for technologies ready to be transferred to industry or clinical partners
  • making recommendations for improving delivery of the Crick’s translation strategy, and
  • encouraging the translational research culture at the Crick by bringing ideas, expertise and experience.



  • David Roblin, Crick Senior Translation Scientific Fellow

Crick members

  • Véronique Birault, Crick Director of Translation
  • Simon Boulton, Crick Group Leader
  • Barbara Domayne-Hayman, Entrepreneur in Residence, Crick


  • Lyndsey Houseman, Crick Head of Translation Operations

External members

  • Gillian Burgess, Executive Vice President, Head of Research, Grünenthal
  • Robin Carr, Chief Executive Officer, Myricx Pharma
  • Alicia El-Haj, Interdisciplinary Chair of Cell Engineering, Birmingham University
  • Manos Perros, President and CEO, Entasis Therapeutics
  • John Pritchard, Independent Consultant
  • David Powell, Chief Scientific Officer, LifeArc
  • Tony Hickson, Chief Business Officer, CRUK
  • Louise Modis, Chief Scientific Officer, Mogrify
  • Mike Romanos, Chief Executive Officer, Microbiotica
  • Jan Wolber, Head of Technology Leader group, GE Healthcare
  • Bryan Williams, Chair of Medicine, UCL

Translation Fund Board

The Translation Fund has been established and provides targeted funding and necessary capital to help develop and commercialise promising scientific discoveries. It supports the development of Crick science toward the marketplace to benefit society. 

The Translation Fund Board was appointed to support the Crick in evaluating projects. Membership consists of 3 internal scientists along with external industry scientists, entrepreneurs and investors. 


  • David Roblin (Chair), Crick Senior Translation Scientific Fellow
  • Véronique Birault, Crick Director of Translation
  • Jeanne Bolger, Consultant and Board member
  • Barbara Domayne-Hayman, Entrepreneur in Residence, Crick
  • Lorenz Mayr, CEO Vector Biopharma
  • Natalie Mount, CEO Adaptate Therapeutics
  • Peter Parker, Crick Translation Advisor
  • Peter Ratcliffe, Crick Clinical Director
  • John Shields, Director, JGS Biopharma
  • Roberto Solari, CEO Myricx


  • Sam Barrell, Crick Deputy Chief Executive Officer
  • Donna Hackett, Crick Head of Commercial Translation
  • Secretariat: Lyndsey Houseman, Crick Head of Translation Operations